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Abstract 1 
 2 
Background: Smoking is a major risk factor for bladder cancer, but the relationship between 3 
smoking cessation after initial treatment and bladder cancer recurrence has been investigated 4 
less frequently and not prospectively yet. 5 
Methods: 722 non-muscle-invasive bladder cancer (NMIBC) patients (pTa, pT1 and CIS) 6 
from the prospective Bladder Cancer Prognosis Programme (BCPP) cohort, selected in the 7 
UK between 2005-2011, provided complete data on smoking behaviour before and up to 5 8 
years after diagnosis. The impact of smoking behaviour on NMIBC recurrence was explored 9 
by multivariable Cox regression models investigating time-to-first NMIBC recurrence. 10 
Results: Over a median follow-up period of 4.21 years, 403 pathologically confirmed 11 
NMIBC recurrences occurred in 210 patients. Only 25 current smokers at diagnosis quit 12 
smoking (14%) during follow-up and smoking cessation after diagnosis did not decrease risk 13 
of recurrence compared to continuing smokers (p=0.352).  14 
Conclusions:  Although quitting smoking after diagnosis might reduce the risk of recurrence 15 
based on retrospective evidence, this is not confirmed in this prospective study because the 16 
number of NMIBC patients quitting smoking before their first recurrence was too low. 17 
Nevertheless, this indicates an important role for urologists and other health care 18 
professionals in promoting smoking cessation in NMIBC.   19 
 
 3 
Introduction 20 
Bladder cancer (BC) is estimated to be the ninth most frequent cancer worldwide with 21 
approximately 400,000  newly diagnosed cases per year [1]. Compared to other cancers, 22 
mortality rates are generally lower for BC [1] since the majority of BCs diagnosed are non-23 
muscle-invasive bladder cancers (NMIBC) [2]. However, NMIBC often recurs [3] and has a 24 
risk of progressing to muscle-invasive bladder cancer (MIBC) [4], events which impact on 25 
the quality of life of the patient [5] and generate high disease management costs [6]. 26 
Although smoking is an established risk factor for BC, its effects has been less 27 
frequently investigated in relation to BC prognosis [7–10]. Although many studies 28 
investigated effectiveness of treatment for NMIBC and MIBC with regard to recurrence, 29 
progression and mortality, most studies did not investigate the effect of smoking or other 30 
factors modifiable by patients on BC prognosis [11]. Nevertheless, the number of studies also 31 
reporting hazard ratios (HRs) for BC recurrence by smoking status at diagnosis has increased 32 
recently and the current body of evidence consistently shows that there is a small association 33 
between smoking and BC recurrence when comparing current smokers to never smokers at 34 
diagnosis [10,12]. However, the impact of smoking cessation after BC diagnosis on 35 
recurrence and mortality has not yet been quantified prospectively [13]. Studies have 36 
investigated the impact of smoking cessation within one year after diagnosis on BC 37 
recurrence, showing a slight decrease in risk of recurrence [14,15], and one study indicating 38 
no effect of quitting after diagnosis on overall or bladder cancer-specific mortality [16]. 39 
The Bladder Cancer Prognosis Programme (BCPP) followed-up BC patients for five 40 
years post-diagnosis and investigated changes in smoking behaviour in relation to the course 41 
of the disease [17]. The principal aim of this study was to investigate whether smoking 42 
cessation post-diagnosis and smoking behaviour pre-diagnosis influences BC recurrence.  43 
 
 4 
Methods  44 
The Bladder Cancer Prognosis programme 45 
This study was conducted within the framework of the West Midlands Bladder Cancer 46 
Prognosis Programme (BCPP), a cohort study in the United Kingdom. Details of the study 47 
are described elsewhere [17]. In brief, individuals were included between December 2005 48 
and October 2011 after referral to participating urology centres due to symptoms suspicious 49 
of BC and followed for a maximum of 5 years from diagnosis. Patients with previous cancer 50 
of the urethra, bladder, ureter, or renal pelvis within the last decade were excluded. The study 51 
was ethically-approved (06/MRE04/65) and all participants gave written informed consent.  52 
 53 
Data collection 54 
At or around time of diagnosis, trained research nurses used semi-structured face-to-face 55 
interviews and questionnaires to collect data on social support, health-related quality of life, 56 
sociodemographics, medical history, and health-related behaviours including smoking 57 
behaviour. Variables on smoking behaviour included current smoking status (never, former, 58 
current), duration (years of smoking), intensity (cigarettes per day), smoking cessation (in 59 
years) and tobacco type (filter, non-filter or rolled cigarettes, cigar or pipe). Monthly smoking 60 
status was also assessed retrospectively by postal questionnaires that were sent out to 61 
participants yearly until the end of follow-up.  62 
 63 
Smoking status at diagnosis and during follow-up 64 
A combined smoking status variable was created indicating continuing smokers, former 65 
smokers who consistently abstained, never smokers, former smokers who started smoking 66 
again, and current smokers who quit smoking post-diagnosis. Patients were considered 67 
quitters when they abstained consistently, so smokers who quit for 3 months and then started 68 
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again were considered as continuing smokers. Furthermore, for each participant that reported 69 
smoking cessation during follow-up it was confirmed whether this occurred before or after 70 
their first recurrence. If patients quit smoking after their first recurrence, they were 71 
considered as continuing smokers in the time-to-first recurrence analysis. 72 
 73 
Population at risk 74 
Of the 1,550 cases who agreed to participate, 231 were subsequently identified as not having 75 
BC. Patients who presented with MIBC (n=275) disease at diagnosis were excluded from 76 
analysis because they are fundamentally different from NMIBC with regard to recurrence. 77 
Patients with squamous or adeno-carcinomas of non-urothelial origin or with bladder cancer 78 
as secondary carcinoma were excluded (n=41). In addition to patients presenting with Ta and 79 
T1 tumours, carcinoma in situ (CIS) tumours were included (n=16) since they have an 80 
increased risk of recurrence [18]. In total, 846 (84%) of these patients had provided data on 81 
smoking behaviour at diagnosis and during follow-up and remained under follow-up within 82 
the cohort study. Of the included 846 NMIBC patients, there were 116 patients with 83 
unknown recurrent tumour stage. These 116 unconfirmed events were excluded for other 84 
analyses as well as 8 cases who had radiotherapy (on suspicion of being MIBC cases) 85 
resulting in a NMIBC patient population at risk of recurrence of 722. 86 
No systematic guidance or tools were provided to enable patients to quit smoking 87 
after diagnosis, so care as usual was applied by all participating urologists. 88 
 89 
Statistical analysis 90 
 BC recurrence was defined as a new tumour that was the same stage as the primary 91 
tumour (Ta or T1) but also when a primary Ta patient had a T1 recurrence. Patients that 92 
progressed from T1 to T2 disease were not counted as a recurrence but as a progression 93 
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event. Unfortunately, there were not enough events to also consider biological progression 94 
within this sample of NMIBC patients, as defined in the BCPP cohort [19]. Therefore, this 95 
study only focussed on confirmed recurrence events and patients who experienced a 96 
progression event were censored in the survival analysis when the progression event was 97 
diagnosed. 98 
The impact of smoking behaviour on BC recurrence was explored by Cox regression 99 
models—with time since initial transurethral resection of the bladder tumour (TURBT) as the 100 
time-metric—investigating possible differences in likelihood of a first recurrence. We 101 
explored two different Cox regression models: one adjusted for age at diagnosis and sex 102 
(model 1) and one additionally adjusted for BC stage, grade, tumour size and number of 103 
tumours at diagnosis (model 2). This set of confounders was chosen since they are markers of 104 
NMIBC prognosis and are factors that contribute to European Association of Urology (EAU) 105 
risk stratification for clinical decisions[20]. Moreover, they are potentially associated with 106 
smoking behaviour at diagnosis [21]. Consequently, conditional risk set modelling was 107 
applied to investigate time between multiple recurrent events and analysis time was reset at 108 
each event [22]. For this analysis, reresection of tumours was added to model 2 as a 109 
confounder. The proportional hazards assumption was checked in all models using 110 
Schoenfeld residuals. Cumulative incidence functions (CIF) corrected for competing risks 111 
(death) were made [23]. 112 
Furthermore, the differences in mean number of recurrences over 5 years between 113 
never smokers, former smokers and continuing smokers were compared using a multivariable 114 
ANOVA model correcting for pairwise comparisons using Tukey’s HSD. There were not 115 
enough BC-related death events (45) or confirmed progression events (19) to allow for 116 
separate analyses. A similarly low number of progression events has been observed in a large 117 
(n=718) NMIBC patient sample before [24]. 118 
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NMIBC patients who died before the end of follow-up (n=157) were censored at time 119 
of death and patients who underwent cystectomy (n=15) were censored at the date of 120 
cystectomy (13). Other patients were considered lost to follow-up when the date on which 121 
patients were last seen in the hospital for bladder cancer-related therapy or the date on which 122 
they filled in their last follow-up questionnaire was before the end of follow-up (5 years).   123 
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Results 124 
Number of recurrences and characteristics of population at risk 125 
All 722 patients at risk of recurrence were followed over a median period of 4.21 years (IQR 126 
= 2.64-5.00 years). The majority of patients (506, 70%) were followed for at least 3 years. 127 
Over this period of follow-up, 210 NMIBC patients experienced at least one confirmed 128 
recurrence event. These 210 NMIBC patients accumulated a total of 403 confirmed 129 
recurrence events in the cohort.  130 
Most cases were male (79%) and around the age of 70 (Table 1). Furthermore, 131 
continuing smokers seemed to be underrepresented in the low EAU risk group (12%), those 132 
who quit smoking seemed more likely to be younger and female, and continuing smokers 133 
seemed more likely to present with multiple tumours at diagnosis (Table 1). In the 134 
multivariate models, 26 patients were not included in the analysis due to missing data on age 135 
(n=7), number of tumours at diagnosis (n=15) and tumour size (n=4). Because participants 136 
were recruited from multiple centers, patients were treated by multiple urologists with 137 
different individual thresholds to perform certain therapies. Therefore, not all patients were 138 
treated exactly according to the EAU guidelines [20], which is often the case in actual 139 
clinical practice [25].   140 
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Table 1. Patient characteristics at diagnosis & number of recurrences over 5 years for 141 
722 NMIBC patients treated with transurethral resection by smoking category.  142 
  
Overall 
(n=722) Combined smoking status   
    
Never 
smoker 
(n=103) 
Former 
smoker 
(n=266) 
Continuing 
Smoker 
(n=186) 
Former 
smoker who 
started 
again 
(n=150) 
Quitters 
after 
diagnosis 
(n=17) 
p-
value* 
Age in years 
      
<0.001 
Median (25th-75th 
percentile) 71 (63-77) 72 (61-79) 72 (67-79) 67 (57-74) 72 (64-77) 62 (56-67) 
 Sex 
      
<0.001 
Male 573 (79%) 63 (61%) 231 (87%) 139 (75%) 129 (86%) 11 (65%) 
 Female 149 (21%) 40 (39%) 35 (13%) 47 (25%) 21 (14%) 6 (35%) 
 EAU risk group 
      
<0.001 
Low 128 (18%) 28 (27%) 71 (27%) 23 (12%) 4 (3%) 2 (12%) 
 Intermediate 383(53%) 50 (49%) 131 (49%) 97 (52%)  91 (61%) 14 (82%) 
 High 211 (29%) 25 (24%) 64 (24%) 66 (36%) 55 (37%) 1 (6%) 
 Number of tumours 
      
<0.001 
1 429 (61%) 70 (70%) 179 (69%) 100 (55%) 69 (46%) 11 (65%) 
 2-7 258 (36%) 27 (27%) 74 (28%) 76 (42%) 75 (50%) 6 (35%) 
 >=8 22 (3%) 3 (3%) 8 (3%) 6 (3%) 5 (3%) 0 (-) 
 Tumour size 
      
0.068 
<3cm 445 (63%) 68 (68%) 174 (67%) 105 (58%) 85 (57%) 13 (76%) 
 >=3cm 260 (37%) 32 (32%) 84 (33%) 77 (42%) 63 (43%) 4 (24%) 
 Grade 
      
0.001 
1 212 (30%) 34 (34%) 99 (38%) 51 (28%) 26 (17%) 2 (13%) 
 2 257 (36%) 34 (34%) 75 (28%) 73 (40%) 66 (44%) 9 (56%) 
 3 245 (34%) 33 (33%) 90 (34%) 60 (32%) 57 (38%) 5 (31%) 
 Stage 
      
0.590 
pTa 476 (66%) 68 (66%) 184 (69%) 115 (62%) 95 (63%) 14 (82%) 
 pT1 239 (33%) 35 (34%) 79 (30%) 69 (37%) 53 (35%) 3 (18%) 
 pCis 7 (1%) 0 (-) 3 (1%) 2 (1%) 2 (1%) 0 (-) 
 No of recurrences 
      
0.337 
1 108 (51%) 18 (62%) 28 (46%) 33 (53%) 27 (52%) 2 (33%) 
 2 46 (22%) 6 (21%) 16 (26%) 16 (26%) 6 (11%) 2 (33%) 
 >3 56 (27%) 5 (17%) 17 (28%) 13 (21%) 19 (37%) 2 (33%) 
 Smoking intensity 
      
0.076 
1-9 cigarettes 128 (29%) NA 55 (30%) 23 (21%) 42 (34%) 8 (50%) 
 10-19 cigarettes 140 (32%) NA 53 (28%) 42 (38%) 42 (34%) 3 (19%) 
 >20 cigarettes 167 (38%) NA 78 (42%) 45 (41%) 39 (32%) 5 (31%) 
 Smoking duration 
      
<0.001 
1-9 years 45 (10%) NA 26 (14%) 2 (2%) 16(14%) 1 (6%) 
 10-19 years 83 (19%) NA 43 (23%) 10 (9%) 29 (25%) 1 (6%) 
 20-29 years 87 (20%) NA 46 (25%) 12 (11%) 27 (23%) 2 (13%) 
 30-39 years 88 (21%) NA 37 (20%) 28 (25%) 19 (16%) 4 (25%) 
 >40 years 127 (30%) NA 32 (17%) 60 (54%) 27 (23%) 8 (50%) 
 Smoking cessation 
      
0.051 
<20 years 48 (12%) NA 23 (9%) NA 25 (17%) NA 
 21-40 years 208 (51%) NA 134 (51%) NA 74 (49%) NA 
 >40 years 155 (38%) NA 104 (40%) NA 51 (34%) NA   
*Kruskal-Wallis test for continuous and chi-square test for categorical variables 
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Associations between smoking behaviour pre and post-diagnosis and BC recurrence 143 
Although HR estimates for smoking cessation pre-diagnosis indicated a protective 144 
association with BC recurrence, the p for linear trend was not statistically significant 145 
(ptrend=0.126) and therefore the association cannot be considered as strong (Table 2). No 146 
association between smoking status and risk of recurrence was observed in the multivariable 147 
model (Table 2). Interestingly, when compared to continuing smokers (HR=1.04, 95% 148 
CI=0.65-1.66) HRs were similar for those who quit smoking (p=0.352) and former smokers 149 
who started again post-diagnosis (p=0.431) (Table 2). Additionally, the cumulative incidence 150 
function shows that cumulative incidence of BC recurrence was lowest for former smokers 151 
and never smokers (Figure 1). 152 
 153 
Insert Figure 1 here 154 
 155 
Figure 1. Cumulative incidence functions with correction for competing risk (death) 156 
indicating cumulative incidence of first recurrence per category of smoking 157 
status in NMIBC patients treated with TURBT. 158 
 159 
Only 25 smokers (14%) of the 174 current smokers originally recorded at diagnosis 160 
quit smoking at any point during follow-up. Three quitters were excluded for full analysis for 161 
not having information on their date last seen and another five had missing data regarding the 162 
invasiveness of their recurrent events. Of the 480 former smokers at diagnosis, 172 (36%) 163 
started smoking (any form of tobacco) again post-diagnosis in all included 846 NMIBC 164 
patients.  165 
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Exposure to environmental tobacco smoke during childhood (HR=1.17, 95%CI=0.81-166 
1.68) or adulthood (HR=1.02, 95%CI=0.76-1.36) did not seem to have any impact on time to 167 
first recurrence (Table 2).  168 
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Table 2. Cox regression analysis investigating the association between combined 169 
smoking status, smoking cessation before diagnosis and passive smoking and time-to-170 
first recurrence in NMIBC patients treated with TURBT. 171 
  Age & sex adjusted Multivariable model* 
  HR 95% CI 
number 
of events 
/ patients 
at risk HR 95% CI 
number 
of events 
/ patients 
at risk 
Combined smoking 
status 
  
  
   Never smoker 1.00 ref 29/103 1.00 ref 28/99 
Former smoker 0.79 0.51-1.24 61/266 0.78 0.48-1.24 59/254 
Continuing smoker 1.17 0.75-1.83 62/186 1.04 0.65-1.66 61/180 
  
  
  
  
 
Former smoker who 
started again** 
1.04 0.65-1.64 51/150 0.87 0.53-1.41 49/146 
Current smoker who 
quit smoking*** 
1.25 0.52-3.00 6/17 1.47 0.63-3.41 6/17 
Smoking cessation 
(in years) ****   
 
  
   <20 years 0.81 0.46-1.43 15/48 0.82 0.46-1.46 15/47 
21-40 years 0.76 0.53-1.08 57/208 0.74 0.51-1.08 54/200 
>40 years 0.67 0.44-1.02 39/155 0.71 0.46-1.09 38/148 
    
 
  
   p for trend 0.070     0.126     
Exposed to passive 
smoking during 
childhood? 
      
 
 No 1.00 ref 36/142 1.00 ref 35/138 
Yes 1.23 0.86-1.75 173/576 1.17 0.81-1.68 168/554 
Exposed to passive 
smoking during 
adulthood? 
      
 
 No 1.00 ref 74/261 1.00 ref 74/261 
Yes 1.03 0.77-1.38 135/454 1.02 0.76-1.36 135/454 
* All estimates adjusted for age, sex, stage, grade, tumour size and number of 
tumours 
 ** Former smoker who started again and current smoker who quit smoking not included in 
former smokers at diagnosis 
*** Smokers who quit after their first event are considered as current smokers 
 **** Reference category = current smokers at diagnosis, estimates also include former 
smokers who started again after diagnosis 
  172 
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 Table 3 shows HRs for time to first recurrence by smoking intensity, duration and 173 
pack-years. No linear trends were observed although the highest categories showed the 174 
highest point estimates for both smoking intensity and pack years. For smoking duration the 175 
HRs were divergent and did not indicate any trend (ptrend=0.729) at all.   176 
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Table 3. Multivariable Cox regression analysis concerning the association between  177 
smoking pack-years, intensity and duration (recorded at diagnosis) with time to first  178 
recurrence in NMIBC patients treated with TURBT. 179 
 180 
  Age & sex adjusted Multivariable model* 
  HR 95% CI 
number of 
events / 
patients at risk 
HR 95% CI 
number of 
events / 
patients at risk 
              
Never smoker 1.00 ref 29/103 1.00 ref 28/99 
              
Pack-years             
1-9 packyears 0.86 0.53-1.42 36/141 0.81 0.48-1.37 34/134 
10-19 packyears 0.95 0.54-1.67 22/81 0.92 0.51-1.65 22/80 
20-29 packyears 0.93 0.49-1.77 15/58 0.81 0.42-1.60 15/57 
30-39 packyears 0.70 0.35-1.43 11/55 0.60 0.30-1.22 11/53 
>40 packyears 1.28 0.76-2.14 30/86 1.14 0.66-1.97 29/83 
              
p for trend 0.365     0.688     
Smoking intensity 
(cigarettes/day)             
1-9 cigarettes 0.83 0.50-1.38 32/128 0.81 0.47-1.38 30/122 
10-19 cigarettes 0.75 0.45-1.28 31/140 0.61 0.35-1.07 31/138 
20+ cigarettes 1.24 0.79-1.96 55/167 1.16 0.72-1.85 54/160 
              
p for trend 0.112     0.198     
Smoking duration (in 
years)             
1-9 years 1.03 0.52-2.05 12/45 0.97 0.48-1.95 12/43 
10-19 years 0.94 0.54-1.62 22/83 0.85 0.48-1.50 21/78 
20-29 years 0.79 0.45-1.39 21/87 0.79 0.44-1.44 20/85 
30-39 years 1.08 0.61-1.89 26/88 0.93 0.52-1.66 25/85 
40+ years 1.00 0.60-1.64 36/127 0.88 0.52-1.49 36/124 
              
p for trend 0.917     0.729     
* All estimates adjusted for age, sex, stage, grade, tumour size and number of tumours at 
diagnosis   
  181 
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When considering multiple events that have occurred in patients (Table 4) the HRs 182 
are similar to the time to first recurrence analysis (HR for continuing vs never smokers is 183 
1.10, 95%CI=0.72-1.69). However, continuing smokers seemed to have experienced more 184 
recurrences than never smokers on average over 5 years on average, however not 185 
significantly (0.64 vs 0.45, p=0.308). 186 
 187 
Table 4. Conditional risk set model investigating time between multiple recurrence  188 
events in NMIBC patients treated with TURBT by smoking status at diagnosis and 189 
after diagnosis. 190 
  HR* 95% CI 
number of 
events / 
patients at 
risk 
Mean number of 
recurrences over 5 
years (95% CI) 
Smoking status 
    Never smoker 1.00 ref 43/99 0.45 (0.28-0.63) 
Former smoker 0.71 0.47-1.08 108/254 0.45 (0.33-0.57) 
Continuing smoker 1.10 0.72-1.69 116/180 0.64 (0.47-0.81) 
     
  
  
Former smoker who started again 0.89 0.56-1.43 108/146 0.82 (0.57-1.06) 
Current smoker who quit smoking** 0.85 0.35-2.04 18/19 0.84 (0.10-1.58) 
* All estimates adjusted for age, sex, stage, grade, tumour size, number of tumours and reresection of 
recurrent tumour 
** Smokers who have quit after their first event (n=2) are also included 
   191 
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Discussion 192 
Smoking cessation post-diagnosis and BC recurrence & clinical implications 193 
The reported HRs give reason to believe that quitting smoking does not influence the 194 
likelihood of NMIBC recurrence over 5 years when compared to continuing smokers in our 195 
sample. However, the number of quitters in our prospective sample was small which 196 
complicates drawing conclusions for this group. Another (retrospective) patient cohort study 197 
which assessed smoking cessation post-diagnosis concluded that quitting smoking 198 
significantly reduced risk of recurrence (HR=0.45, 95% CI=0.25-0.83, comparing quitters to 199 
continuing smokers), however the proportion of quitters (~43% of current smokers at 200 
diagnosis) was also considerably larger [14]. In another retrospective cohort study, Fleshner 201 
et al concluded that it remained unclear whether smoking cessation at time of diagnosis is 202 
beneficial with regard to BC recurrence [15] although Aveyard et al. estimated that the 203 
Fleshner study shows a HR of 0.71 (95% CI=0.48-1.05) when comparing quitters to 204 
continuing smokers[26], which is similar to the estimate observed in the study by Chen et al. 205 
Taken together, the limited evidence at this point seems to indicate that quitting smoking at 206 
or closely after diagnosis could reduce risk of recurrence. However, even across several 207 
smoking-related cancer sites such as lung cancer where this association is stronger, evidence 208 
to imply a strong, causal relationship between smoking behaviour after diagnosis and 209 
recurrence is still limited [27] so more prospective research is needed. 210 
Considering the prolonged latency period for the development of BC after exposures 211 
[2], it is credible that the association between altering smoking behaviour post-diagnosis and 212 
likelihood of a first recurrence or multiple recurrences over 5 years is not as strong as the 213 
association between smoking and carcinogenesis. Similarly, epidemiological evidence 214 
suggests that pre-diagnostic smoking cessation does not immediately lower the risk of BC 215 
[28], also indicating a longer latency period than 5 years. Furthermore, it is considered that a 216 
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first BC recurrence is often the result of incomplete resection and/or tumour cell re-217 
implantation, and that genuine new tumour formation only plays a more important role in 218 
later recurrences [29]. It is therefore reasonable to suggest that, because of the DNA-219 
damaging effects of cigarette smoke [30], modifying smoking behaviour may only influence 220 
later recurrences and possibly those that may occur beyond the follow-up period of 5 years 221 
reported here. 222 
 Notwithstanding the results from our study, when considering the impact of 223 
comorbidities on overall survival in BC patients [31] which include several smoking-related 224 
diseases [32] and other evidence indicating beneficial and significant results of post-225 
diagnostic smoking cessation in retrospective studies [14,15], it is evident that smoking 226 
cessation should be encouraged for NMIBC patients at diagnosis. 227 
It is striking that only 14% of current smokers at diagnosis in our sample quit 228 
smoking post-diagnosis. There are examples of succesful smoking cessation interventions in 229 
urology [33], and several studies found that when patients were diagnosed with BC they were 230 
more likely to quit smoking [34,35]. Therefore, urologists should continue to improve 231 
smoking cessation counselling in newly diagnosed NMIBC patients and to be current on the 232 
available tools to improve smoking cessation figures. Moreover, more intervention clinical 233 
research investigating smoking cessation programmes in NMIBC patients is warranted. 234 
 235 
Smoking behaviour pre-diagnosis & exposure to environmental tobacco smoke 236 
Smoking cessation was most beneficial, with regard to reducing the risk of recurrence, the 237 
longer before diagnosis it happened compared to continuing smokers. This was the strongest 238 
association observed in our study and has been observed in other studies as well, although not 239 
consistently [12]. Other results were in line with earlier studies investigating smoking status 240 
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at diagnosis and BC recurrence as well, by indicating a slightly increased risk of recurrence 241 
in NMIBC patients for current smokers compared to never smokers in a meta-analysis [10].  242 
Another recent study not included in the aforementioned meta-analysis shows similar 243 
HRs (HR=1.49, 95%C.I.=0.95-2.33) for current smokers at diagnosis [8]. However, when 244 
including this study and our study (data from continuing smokers) in the meta-analysis the 245 
pooled HR barely changes from 1.27 (95%CI=1.09-1.46) to 1.26 (95% CI= 1.12-1.40) [10], 246 
indicating a significantly increased risk of recurrence for current smokers at diagnosis 247 
compared to never smokers. Possibly, the lack of association for continuing smokers in this 248 
study can be explained through multiple synchronous tumours being present at diagnosis in 249 
epithelial tumours. This theory of “field cancerization” proposes that (pre-)malignant 250 
transformation of cells has already occurred at different sites across the urothelium, 251 
explaining why (changing) smoking exposure will not have a large impact on disease 252 
prognosis [36].  253 
Additonally, given that recent reviews indicate no considerable heterogeneity between 254 
studies that do not show an association between environmental tobacco smoke and risk of 255 
BC, it is unlikely that we would have shown any substantial association with BC recurrence 256 
either [37,38]. 257 
Because no substantial association between smoking status pre-diagnosis and BC 258 
recurrence was observed in adjusted models it is possible that the tumour characteristics 259 
associated with BC recurrence (stage, grade, tumour size, number of tumours) included as 260 
confounders in these models overshadow the effects of smoking behaviour in determining 261 
risk of BC recurrence [21] and possible also mortality since no association between quitting 262 
smoking after diagnosis and all-cause or bladder-cancer-speficic mortality was observed in a 263 
large retrospective cohort study[16]. Moreover, since current smokers at diagnosis in our 264 
cohort have been associated with having a higher stage, higher grade and larger tumour size 265 
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compared to never smokers [39], smoking behaviour might play a more crucial role in 266 
determining risk of recurrence already before diagnosis through promoting unfavourable 267 
tumour characteristics associated with BC recurrence at diagnosis, although in a Dutch cohort 268 
of 323 UBC patients there was only a weak association between smoking intensity and 269 
increased risk of a more aggressive tumour type [40].  270 
 271 
Strengths and weaknesses 272 
Despite the prospective nature of our study there were some limitations restricting the 273 
analyses. Due to the relatively short follow-up of this study, long term effects of smoking 274 
cessation post-diagnosis could not be assessed and the number of deaths due to BC in the 275 
NMIBC patients within our cohort was too low for Cox regression analysis. Also, it was not 276 
possible to obtain detailed information on adjuvant therapy for all patients, so differences in 277 
adjuvant therapy could not be considered in the statistical analysis. Additionally, we did not 278 
correct for biomarkers of BC recurrence such as mutations in the FGFR3 or TP53 genes [41], 279 
although they might work together with smoking intensity in predicting BC outcome [42].  280 
Furthermore, one of the caviats of using only self-reported questionnaire data to 281 
assess smoking exposure was likely demonstrated in our sample of NMIBC patients. The 282 
large proportion (about 1 in 3) of former smokers pre-diagnosis who reported to have started 283 
smoking again post-diagnosis is implausible and is probably observed due to 284 
misclassification of either the questionnaire at baseline or during follow-up. A high 285 
misclassification rate (47%) when comparing self-reported data on smoking behaviour to 286 
cotinine values in blood was also shown in another sample of bladder cancer patients 287 
undergoing surveillance [43]. Preferably, future studies should consider more reliable ways 288 
of verifying smoking exposure through biochemical analysis. 289 
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Unfortunately, at the start of the study we did not anticipate this small proportion of 290 
quitters after diagnosis which is why the analysis concerning quitters is underpowered.  291 
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Conclusion 292 
Although quitting smoking after diagnosis might reduce probability of recurrence based on 293 
retrospective evidence, the number of NMIBC patients quitting smoking in our prospective 294 
study was low. This indicates an important role for urologists and other health care 295 
professionals in promoting smoking cessation in NMIBC. Based on the current evidence, 296 
smoking cessation pre-diagnosis seems to have the largest impact on reducing risk of 297 
recurrence after NMIBC diagnosis.  298 
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